BG45|cas:926259-99-6|西域试剂

BG45,99.95%

产品编号：Bellancom-18712| CAS NO：926259-99-6| 分子式：C₁₁H₁₀N₄O| 分子量：214.22

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-18712	￥600.00	杭州北京（现货）
Bellancom-18712	￥850.00	杭州北京（现货）
Bellancom-18712	￥2800.00	杭州北京（现货）
Bellancom-18712	￥4320.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BG45

产品介绍

BG45 是一种有效的 HDAC3 抑制剂，抑制 HDAC3、HDAC1、HDAC2 和 HDAC6 的 IC₅₀ 值分别为 0.289、2、2.2 和 >20 μM。BG45 选择性靶向多发性骨髓瘤 (MM) 细胞，诱导 caspase 依赖性凋亡 (apoptosis)。

生物活性

BG45 is a potent HDAC3 inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis.

体外研究

BG45 (1.875-30 µM; 48 and 72 h) targets multiple myeloma (MM) cells and inhibits cell growth in a dose-dependent manner.
BG45 (15 µM; 0-48 h; MM.1S cells) induces apoptosis via caspase-3/PARP cleavage.
BG45 (10 and 20 µM; 12 h; MM.1S cells) induces acetylation of histone H2A, H3, and H4 in a dose-dependent manner.
BG45 (10 and 20 µM; 10 h; MM.1S cells) induces multiple myeloma (MM) cells toxicity is associated with hyperacetylation of histones and STAT3 and downregulation of p-STAT3.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	MM.1S, RPMI8226, U266, OPM1, and H929 cells
Concentration:	1.875, 3.75, 7.5, 15, and 30 µM
Incubation Time:	48 and 72 hours
Result:	Inhibited multiple myeloma (MM) cells growth in a dose-dependent manner.

Western Blot Analysis

Cell Line:	MM.1S cells
Concentration:	15 µM
Incubation Time:	0, 6, 12, 24, and 48 hours
Result:	Induced caspase-dependent apoptosis in multiple myeloma (MM) cells.

Western Blot Analysis

Cell Line:	MM.1S cells
Concentration:	10 and 20 µM
Incubation Time:	12 hours
Result:	Increased acetylation of histone in a dose-dependent manner.

Western Blot Analysis

Cell Line:	MM.1S cells
Concentration:	10 and 20 µM
Incubation Time:	10 hours
Result:	Downregulated p-STAT3 in a dose-dependent manner. Increased acetylation of STAT3 in MM.1S cells.

体内研究
(In Vivo)

BG45 (15-50 mg/kg; i.p.; 5 days a week for 3 weeks; CB17 SCID mice with MM.1S xenograft model) inhibits human multiple myeloma (MM) cells growth and enhances bortezomib (HY-10227) induced cytotoxicity in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17 SCID mice (48-54 days old) with MM.1S xenograft model
Dosage:	15 and 50 mg/kg
Administration:	Intraperitoneal injection; 5 days a week for 3 weeks
Result:	Inhibited MM tumor growth in a dose-dependent fashion. Enhanced either single agent activity in combination with bortezomib (HY-10227).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17 SCID mice (48-54 days old) with MM.1S xenograft model
Dosage:	15 and 50 mg/kg
Administration:	Intraperitoneal injection; 5 days a week for 3 weeks
Result:	Inhibited MM tumor growth in a dose-dependent fashion. Enhanced either single agent activity in combination with bortezomib (HY-10227).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17 SCID mice (48-54 days old) with MM.1S xenograft model
Dosage:	15 and 50 mg/kg
Administration:	Intraperitoneal injection; 5 days a week for 3 weeks
Result:	Inhibited MM tumor growth in a dose-dependent fashion. Enhanced either single agent activity in combination with bortezomib (HY-10227).

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 48 mg/mL (224.07 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.6681 mL	23.3405 mL	46.6810 mL
5 mM	0.9336 mL	4.6681 mL	9.3362 mL
10 mM	0.4668 mL	2.3340 mL	4.6681 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (11.67 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.67 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (11.67 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.67 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明